CHC promotes tumor growth and angiogenesis through regulation of HIF-1α and VEGF signaling

Kuo Hua Tung, Cheng Wei Lin, Chun Chen Kuo, Li Tzu Li, Ya Hsun Kuo, Chung Wu Lin, Han Chung Wu

Research output: Contribution to journalArticlepeer-review

29 Citations (Scopus)


Pancreatic adenocarcinoma is an aggressive disease with a high mortality rate. In this study, we have newly generated a monoclonal antibody (mAb), Pa65-2, which specifically binds to pancreatic cancer cells and tumor blood vessels. The target protein of Pa65-2 is identified as human clathrin heavy chain (CHC). In vitro and In vivo study showed that suppression of CHC either by shRNA or by Pa65-2 inhibited tumor growth and angiogenesis. One of the key functions of CHC was to bind with the hypoxia-inducing factor (HIF)-1α protein, increasing the stability of this protein and facilitating its nuclear translocation, thereby regulating the expression of VEGF. Taken together, our findings indicate that CHC plays a role in the processes of tumorigenesis and angiogenesis. Pa65-2 antibody or CHC shRNA can potentially be used for pancreatic cancer therapy.

Original languageEnglish
Pages (from-to)58-67
Number of pages10
JournalCancer Letters
Issue number1
Publication statusPublished - Apr 30 2013
Externally publishedYes


  • Angiogenesis
  • Clathrin heavy chain
  • HIF-1α
  • Monoclonal antibody
  • Pancreatic cancer

ASJC Scopus subject areas

  • Cancer Research
  • Oncology


Dive into the research topics of 'CHC promotes tumor growth and angiogenesis through regulation of HIF-1α and VEGF signaling'. Together they form a unique fingerprint.

Cite this